4D Molecular Therapeutics Presents Phase 2 Trial Results for Wet AMD at ASRS Meeting
4D Molecular Therapeutics Presents Phase 2 Trial Results for Wet AMD at ASRS Meeting
4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 24-week landmark data from the Population Extension cohort of the PRISM Phase 2 Clinical Trial, which evaluated intravitreal 4D-150 in a broad wet AMD patient population. The data were presented by Raj K. Maturi, M.D., in an oral presentation titled, "Phase 2 Population Extension Cohort in the PRISM Trial Evaluating 4D-150 in Adults with Neovascular Age-related Macular Degeneration," at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting held in Stockholm, Sweden.
4d molecular therapeutics（纳斯达克：FDMt，4DMt或公司）是一家领先的临床遗传医学公司，致力于释放遗传医学以治疗大型市场疾病的全部潜力。今天，公司宣布了PRISm第二阶段临床试验人群扩展队列的24周初步中期里程碑数据的积极结果，该研究评估了广泛的患有激素依赖性湿性黄斑变性的患者中，4D-150的视网膜内注射。这些数据是由Raj k. Maturi博士在一次口头报告中介绍的，题目为“ PRISm试验中评估4D-150对与新生血管性年龄相关的黄斑变性成人的人群扩展队列第2期的结果”，在瑞典斯德哥尔摩举行的美国视网膜专家协会（ASRS）年度科学会议上。